Arun Keepanasseril

Hamilton, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 26, 2026

Evaluation of the determinants of FVIII/FIX levels, bleeding score, and health-related quality of life in the Canadian hemophilia carriers (CHiC) study.

Evaluation of the determinants of FVIII/FIX levels, bleeding score, and health-related quality of life in the Canadian hemophilia carriers (CHiC) study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 09, 2026

Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry.

Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry.

Journal: Blood advances

Published: December 19, 2025

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

Journal: Research and practice in thrombosis and haemostasis

Published: October 29, 2025

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry.

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: August 22, 2025

Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources.

Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 16, 2025

2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 10, 2025

Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study.

Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 31, 2025

Developing a Two-Sided Decision Box to Facilitate Shared Decision-Making for Switching From Conventional to Pharmacokinetic-Tailored Prophylaxis in Haemophilia.

Developing a Two-Sided Decision Box to Facilitate Shared Decision-Making for Switching From Conventional to Pharmacokinetic-Tailored Prophylaxis in Haemophilia.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: February 20, 2025

Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.

Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 15, 2023

Scoping review of the recommendations and guidance for improving the quality of rare disease registries.

Scoping review of the recommendations and guidance for improving the quality of rare disease registries.

Journal: Orphanet journal of rare diseases

Published: November 21, 2023

Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.

Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.

Journal: Research and practice in thrombosis and haemostasis

Published: November 01, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026